产品
编 号：F464783
分子式：C15H20N2O4
分子量：292.33
分子式：C15H20N2O4
分子量：292.33
产品类型
规格
价格
是否有货
结构图
CAS No: 802915-53-3
产品详情
生物活性：
Fusarochromanone (FC-101) is a fungal metabolite with potent anti-angiogenic and anti-cancer activity. Fusarochromanone-activated JNK pathway is attributed to induction of reactive oxygen species (ROS).
体内研究：
Fusarochromanone (8 mg/kg; IP; 5 days per week; for 3.5 weeks) Is well tolerated, non-toxic, and achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day.Animal Model:SCID Beige mice (CB17/Icr.Cg-PrkdcscidLystbg/Crl) injected with SRB12-p9 cells
Dosage:8 mg/kg
Administration:IP; 5 days per week; for 3.5 weeks
Result:Achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day.
体外研究：
Fusarochromanone (FC101; 10 μM; 24 hours) induces apoptosis and an increase in proportion of cells in the sub-G1 phase in both HaCat and P9-WT cell lines. Fusarochromanone (FC101; 0-1 μM; 24 h) induces the cleavage of both caspase-3 and PARP, a well-known substrate for activated caspases. FC101 does not affect the expression of the anti-apoptotic proteins, Bcl-2, Bcl-XL, Mcl-1, or the pro-apoptotic proteins BAD, BAK, BAX.Fusarochromanone (FC101) exhibits very potent in-vitro growth inhibitory effects (IC50 ranging from 10 nM-2.5 μM) against HaCat (pre-malignant skin), P9-WT (malignant skin), MCF-7 (low malignant breast), MDA-231 (malignant breast), SV-HUC (premalignant bladder), UM-UC14 (malignant bladder), and PC3 (malignant prostate) in a time-course and dose-dependent manner, with the UM-UC14 cells being the most sensitive.
Fusarochromanone (FC-101) is a fungal metabolite with potent anti-angiogenic and anti-cancer activity. Fusarochromanone-activated JNK pathway is attributed to induction of reactive oxygen species (ROS).
体内研究：
Fusarochromanone (8 mg/kg; IP; 5 days per week; for 3.5 weeks) Is well tolerated, non-toxic, and achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day.Animal Model:SCID Beige mice (CB17/Icr.Cg-PrkdcscidLystbg/Crl) injected with SRB12-p9 cells
Dosage:8 mg/kg
Administration:IP; 5 days per week; for 3.5 weeks
Result:Achieved a 30% reduction in tumor size at a dose of 8 mg/kg/day.
体外研究：
Fusarochromanone (FC101; 10 μM; 24 hours) induces apoptosis and an increase in proportion of cells in the sub-G1 phase in both HaCat and P9-WT cell lines. Fusarochromanone (FC101; 0-1 μM; 24 h) induces the cleavage of both caspase-3 and PARP, a well-known substrate for activated caspases. FC101 does not affect the expression of the anti-apoptotic proteins, Bcl-2, Bcl-XL, Mcl-1, or the pro-apoptotic proteins BAD, BAK, BAX.Fusarochromanone (FC101) exhibits very potent in-vitro growth inhibitory effects (IC50 ranging from 10 nM-2.5 μM) against HaCat (pre-malignant skin), P9-WT (malignant skin), MCF-7 (low malignant breast), MDA-231 (malignant breast), SV-HUC (premalignant bladder), UM-UC14 (malignant bladder), and PC3 (malignant prostate) in a time-course and dose-dependent manner, with the UM-UC14 cells being the most sensitive.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备